Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
Authors:
- David A. PalmaDPDavid A. Palma
- Timothy K. NguyenTNTimothy K. Nguyen
- Keith KwanKKKeith Kwan
- Stewart GaedeSGStewart Gaede
- Mark LandisMLMark Landis
- Richard MalthanerRMRichard Malthaner
- Dalilah FortinDFDalilah Fortin
- Alexander V. LouieALAlexander V. Louie
- Eric FrechetteEFEric Frechette
- George B. RodriguesGRGeorge B. Rodrigues
- Brian YaremkoBYBrian Yaremko
- Edward YuEYEdward Yu
Open Access
- 27 January 2017
- journal article
- research article
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 30
Abstract
A phase II trial was launched to evaluate if neoadjuvant stereotactic ablative radiotherapy (SABR) before surgery improves oncologic outcomes in patients with stage I non-small cell lung cancer (NSCLC). We report a mandated interim safety analysis for the first 10 patients who completed protocol treatment. Operable patients with biopsy-proven T1-2 N0 NSCLC were eligible. SABR was delivered using a risk-adapted fractionation (54Gy/3 fractions, 55/5 or 60/8). Surgical resection was planned 10 weeks later at a high-volume center (>200 lung cancer resections annually). Patients were imaged with dynamic positron emission tomography-computed tomography scans using 18F-fludeoxyglucose (18F-FDG-PET CT) and dynamic contrast-enhanced CT before SABR and again before surgery. Toxicity was recorded using CTCAE version 4.0. Twelve patients were enrolled between 09/2014 and 09/2015. Two did not undergo surgery, due to patient or surgeon preference; neither patient has developed toxicity or recurrence. For the 10 patients completing both treatments, median age was 70 (range: 54–76), 60% had T1 disease, and 60% had adenocarcinoma. Median FEV1 was 73% predicted (range: 54–87%). Median time to surgery post-SABR was 10.1 weeks (range: 9.3–15.6 weeks). Surgery consisted of lobectomy (n = 8) or wedge resection (n = 2). Median follow-up post-SABR was 6.3 months. After combined treatment, the rate of acute grade 3–4 toxicity was 10%. There was no post-operative mortality at 90 days. The small sample size included herein precludes any definitive conclusions regarding overall toxicity rates until larger datasets are available. However, these data may inform others who are designing or conducting similar trials. NCT02136355 . Registered 8 May 2014.Keywords
Funding Information
- Ontario Institute for Cancer Research
This publication has 15 references indexed in Scilit:
- New Strategies in Stereotactic Radiotherapy for OligometastasesClinical Cancer Research, 2015
- Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trialBMC Cancer, 2012
- Lung-cancer related chest events detected by periodical follow-up CT after stereotactic body radiotherapy for stage I primary lung cancer: retrospective analysis of incidence of lung-cancer related chest events and outcomes of salvage treatmentJapanese Journal of Radiology, 2012
- Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literatureRadiotherapy and Oncology, 2012
- The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms — results of an ablate and resect studyEuropean Journal of Cardio-Thoracic Surgery, 2011
- Salvage Lung Resection for Non-small Cell Lung Cancer After Stereotactic Body Radiotherapy in Initially Operable PatientsJournal of Thoracic Oncology, 2010
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinomaCancer Treatment Reviews, 2008
- Outcomes of Risk-Adapted Fractionated Stereotactic Radiotherapy for Stage I Non–Small-Cell Lung CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Neoadjuvant Therapy: An Emerging Concept in OncologySouthern Medical Journal, 2005